PREAMI Study Shows Perindopril Improved Cardiac Function in Elderly Patients Following a Heart Attack
September 04 2005 - 11:39AM
PR Newswire (US)
- Data Presented as Hotline Session at 2005 European Society of
Cardiology (ESC) Meeting - STOCKHOLM, Sweden, Sept. 4
/PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (NASDAQ:CVTX)
announced today that perindopril improved cardiac function,
including left ventricular (LV) remodeling, in elderly patients
following a heart attack, based on data presented today from the
PREAMI (Perindopril and Remodeling in Elderly with Acute Myocardial
Infarction) study during a Hotline session of the ESC Congress 2005
in Stockholm, Sweden. In the study, perindopril reduced the primary
endpoint, a combination of death, hospitalization for heart failure
and LV remodeling, by 38 percent (p
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024